Comparison of a Polymer-Based Paclitaxel-Eluting Stent With a Bare Metal Stent in Patients With Complex Coronary Artery Disease: A Randomized Controlled Trial

Stone, Gregg W.; Ellis, Stephen G.; Cannon, Louis

doi:10.1016/j.accreview.2005.11.049

Cited by 319 publications

(363 citation statements)

References 18 publications

Supporting

Mentioning

329

Contrasting

Unclassified

Order By: Relevance

“…Only a few multicenter clinical studies have reported both clinical and angiographic outcomes for all enrolled patients at follow-up using stents smaller than 2.5 mm in diameter [2][3][4][5][6][7]. There are even fewer studies in which the secondgeneration DESs were used [3,7], and there have been no studies that examined 2.25-mm diameter DESs with a bioresorbable polymer.…”

Section: Introductionmentioning

confidence: 99%

Two-year results after coronary stenting of small vessels in Japanese population using 2.25-mm diameter sirolimus-eluting stent with bioresorbable polymer: primary and long-term outcomes of CENTURY JSV study

Saïto

Ando

Ito

et al. 2018

Cardiovasc Interv and Ther

View full text Add to dashboard Cite

Percutaneous coronary intervention (PCI) in coronary artery disease (CAD) with very small vessels remains challenging. The aim of this study is to evaluate the safety and effectiveness of the 2.25-mm diameter Ultimaster sirolimus-eluting stent in the treatment of Japanese patients with CAD due to lesions in very small vessels. The CENTURY JSV study is a prospective, multicentre, single-arm study. Seventy patients with lesions deemed suitable for implantation of a 2.25-mm diameter stent were enrolled at seven hospitals in Japan. Patients underwent clinical follow-up at 1-, 9-month, 1-, and 2-year after the PCI procedure. The primary endpoint was the major adverse cardiac event (MACE), a composite of cardiac death, target vessel myocardial infarction (MI), and clinically driven target lesion revascularization (TLR) free rate at 9-month following the procedure. The MACE-free rate was 97.1%, and the lower limit of the two-sided 95% confidence interval (CI) was 90.1%, which exceeded the threshold of 80% set as the performance goal. Angiographic in-stent and in-segment late loss at 9-month were 0.22 ± 0.31 and − 0.02 ± 0.34 mm, respectively. Between 9 months and 2 years, two additional TLRs occurred. Stent thrombosis, bleeding and vascular complication did not occur throughout 2 years. The 2.25-mm diameter Ultimaster ® bioresorbable-polymer sirolimus-eluting stent is safe and effective for treating lesions in very small coronary arteries throughout 2 years after stent implantation. Clinical trial registration: UMIN000012928.

show abstract

Section: Introductionmentioning

confidence: 99%

Two-year results after coronary stenting of small vessels in Japanese population using 2.25-mm diameter sirolimus-eluting stent with bioresorbable polymer: primary and long-term outcomes of CENTURY JSV study

Saïto

Ando

Ito

et al. 2018

Cardiovasc Interv and Ther

View full text Add to dashboard Cite

show abstract

“…The high success rates and rare major complications of the in-hospital outcomes corroborate this statement. More recently, both in UA and other clinical presentations of coronary disease, drug-eluting stents, used in 33% of the patients in our investigation, yielded significant improvement in late clinical outcome, based on a marked decrease in additional revascularizations secondary to coronary restenosis 20,21 . Nevertheless, a recent European investigation on the cost-effectiveness of drug-eluting stents demonstrated that UA cases are among those that do not offer significant benefit when used routinely 22 .…”

Section: Peixoto Et Al Unstable Angina Patients Treated With Percutanmentioning

confidence: 99%

Pacientes com angina instável tratados por meio de intervenções coronarianas percutâneas no novo milênio: o que os caracteriza?

Peixoto¹,

Tanajura²,

Sousa³

et al. 2007

Arq. Bras. Cardiol.

View full text Add to dashboard Cite

Objective: To identify clinical and angiographic profiles of patients with unstable angina seen at a tertiary hospital and treated with percutaneous coronary intervention (PCI). Methods:Study of a consecutive series of 1413 patients, selected from a computerized database, who underwent percutaneous revascularization in the three-year period of [2002][2003][2004]. There were no inclusion/exclusion criteria.Results: Systemic arterial hypertension (74%) and hypercholesterolemia (65%) were the classical risk factors for coronary disease most frequently observed. Coronary artery bypass grafting and history of myocardial infarction were found in 24% and 28% of the cases, respectively. The subgroups most commonly treated were the IIB (48%) and IIIB (28%). Clopidogrel was prescribed for 51% of the patients and glycoprotein IIb/IIIa inhibitors, for 7%. Multivessel disease evidenced by coronary angiography was detected in 42% of the cases. Type B2 or C lesions were treated in 64%, 94% of which in native vessels. Restenotic lesions were dilated in 5% of the patients. All interventions were performed using coronary stents, the majority of which (67%) were standard bare-metal stents.Conclusions: 1) Subgroups IIB and IIIB were the most frequently treated (76%); 2) Clopidogrel was the most prescribed antithrombotic agent (51%); 3) Multivessel coronary artery disease was found in 42% of the cases, most of which were complex target lesions located in native vessels; 4) Coronary stent implantation was the chief dilation technique used.Key words: Unstable angina, coronary angioplasty. Unstable angina (UA) is one of the most important medical emergencies because of its high frequency and expressive morbidity and mortality 1,2 . For example, in the United States, approximately 1.3 million patients (p) are hospitalized for this condition each year 3 , a figure that underscores the need for providing the best available treatment for this population.In the second half of the last decade, three randomized clinical trials have proved the superiority of invasive strategy involving coronary angiography and early myocardial revascularization, whenever possible, over the conservative approach [4][5][6] . In this context, percutaneous coronary intervention (PCI) is the revascularization method most widely used. This has been made possible by the development of adjunctive antithrombotic drug therapy (fractionated heparin, glycoprotein IIb/IIIa inhibitors and clopidogrel) and the advent of coronary stents, after which procedural outcomes have become safer and more predictable [4][5][6] . More recently, the introduction of drug-eluting stents has resulted in a significant drop in late clinical events, by considerably reducing angiographic and clinical restenosis rates 7,8 . This investigation sought to identify the main angiographic/ clinical features related to the percutaneous procedure in a consecutive series of patients (p) who underwent PCI in the presence of unstable angina in a very busy tertiary hospital. MethodsA retrospective analysis ...

show abstract

“…3,4 Furthermore, several clinical trials have shown that DES are effective for patients with high-risk lesions or clinical conditions such as calcified lesions, left main coronary artery disease, multivessel disease, and diabetes. 5,6 Calcified coronary lesions are now being routinely treated with DES, namely with sirolimus-eluting stents (SES) or paclitaxel-eluting stents (PES). Although previously reported data regarding CCL mainly addressed its presence or absence in discrete focal target lesions, in some patients, CCL appear angiographically as diffuse long lesions.…”

Section: Introductionmentioning

confidence: 99%

Comparison of Long‐term Outcomes Following Sirolimus‐eluting Stent vs Paclitaxel‐eluting Stent Implantation in Patients with Long Calcified Coronary Lesions

Hur

Nam

Kim

et al. 2009

Clinical Cardiology

View full text Add to dashboard Cite

Background:Although previously reported studies on coronary calcification mainly focused on its presence or absence in discrete focal target lesions, calcified coronary lesions (CCL) angiographically present as diffuse long lesions in some patients. The aim of our study was to evaluate the long-term efficacy of sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES) on long CCL. Methods: A total of 122 patients with 134 lesions (77 patients with 88 lesions for SES and 45 patients with 46 lesions for PES) were enrolled from 3 centers. Long CCL was defined visually as a culprit lesion with type B or C that was mainly due to coronary calcification with >20 mm in total length by coronary angiography. Clinical follow-up was performed at 1 year and angiographic follow-up at 6 to 9 months after procedure. Major adverse coronary events (MACE) were defined as all-cause death, myocardial infarction (MI), and repeat target-lesion revascularization (TLR). Results: There were no statistically significant differences in baseline, procedural, or angiographic characteristics and in 1-year rates of all-cause death, MI, and TLR between the 2 groups (all P = NS [not significant]). Likewise, the cumulative incidence of MACE at 1 year was similar between the 2 groups (7.8% of patients in the SES group vs 4.4% of patients in the PES group, respectively, P = NS). In patients who underwent follow-up angiography, the angiographic binary restenosis rate was 6.2% in the SES group vs 12.1% in the PES group, respectively (P = NS). Conclusion: In patients with long CCL, both SES and PES were comparably effective in either angiographic or clinical long-term outcomes.

show abstract

Comparison of a Polymer-Based Paclitaxel-Eluting Stent With a Bare Metal Stent in Patients With Complex Coronary Artery Disease: A Randomized Controlled Trial

Cited by 319 publications

References 18 publications

Two-year results after coronary stenting of small vessels in Japanese population using 2.25-mm diameter sirolimus-eluting stent with bioresorbable polymer: primary and long-term outcomes of CENTURY JSV study

Two-year results after coronary stenting of small vessels in Japanese population using 2.25-mm diameter sirolimus-eluting stent with bioresorbable polymer: primary and long-term outcomes of CENTURY JSV study

Pacientes com angina instável tratados por meio de intervenções coronarianas percutâneas no novo milênio: o que os caracteriza?

Comparison of Long‐term Outcomes Following Sirolimus‐eluting Stent vs Paclitaxel‐eluting Stent Implantation in Patients with Long Calcified Coronary Lesions

Contact Info

Product

Resources

About